fashion -WSS

fashion

author：Wikipedia 2025-08-25 08:45:49 - browse：2

Anthony Fernandez holds a Wegovy injection, the ALP-1 agonist medication he uses to help curb his food cravings – Obesity medication and science coverage for STAT — A person holds a Wegovy injection pen. Kayana Szymczak for STAT

Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed to prevent heart problems, but policy experts said Medicare patients are still likely to encounter significant barriers getting access to the highly popular and expensive drug.

Medicare previously wasn’t reimbursing for Wegovy, since the federal payer is legally barred from covering weight loss drugs. But the Food and Drug Administration this month approved Wegovy for preventing heart problems in people with obesity and heart disease, leading many to suspect that Medicare would start covering the drug for this usage.

Makers of obesity drugs have been hoping that showing additional benefits beyond weight loss would induce more insurers to cover them. Medicare’s guidance, first reported Thursday, moves in that direction, but experts point out that the private insurers that administer Medicare’s prescription drug benefit — called Part D — can still choose to not include Wegovy on their formularies, especially if they think it would be too costly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Change Healthcare can notify patients about the breach, HHS says

WSS

ASCO: Palliative care found as helpful given virtually as in person

The Pandemic Treaty must support building strong health systems

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Male doctors called my cancer incurable. A female doctor showed it wasn't

hotspot

fashion

focus

Psychedelics group wrestles with new pharma identity

Hospital chaplains balance Covid safety with patients’ spiritual needs

As demand for Covid shots wanes, Moderna seeks its next success

A preacher's new calling: Diversifying neuroscience research

In age of alternative facts, a scholarly course on calling out crap

Ascension's ugly legal battle over care for poor patients in Texas

Anesthesiologist group: stop taking Ozempic before surgery

Profiling embryos to choose those with higher IQs is almost a reality

BioMarin wins approval for gene therapy to treat hemophilia A

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

knowledge

Letters to First Opinion on caregivers, digital health, and more

Change Healthcare can notify patients about the breach, HHS says

American taxpayers paid $1.8 trillion in health care costs in 2022

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

At ASCO, AstraZeneca reports strong data for breast cancer drug

Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

hotspot

focus

hotspot